Clinical outcomes of a remimazolam-based sedation regimen in patients receiving ECMO: a retrospective comparative study - Takeaways - MDSpire

Clinical outcomes of a remimazolam-based sedation regimen in patients receiving ECMO: a retrospective comparative study

  • By

  • Dalong Zhang

  • Ying Liu

  • Tongrui Zhang

  • Yuanjie Shang

  • Huijun Dong

  • Xingguo Niu

  • June 8, 2026

  • 0 min

Share

  • 1

    This study compared remimazolam and midazolam sedation in ECMO patients, focusing on delirium incidence and recovery outcomes.

  • 2

    Delirium occurred in 0% of patients receiving remimazolam compared to 27.3% in those receiving midazolam, with a significant risk difference.

  • 3

    Patients in the remimazolam group had shorter recovery times after decannulation and better-preserved muscle strength than those in the midazolam group.

  • 4

    The study included 52 patients, with 44 receiving veno-arterial ECMO, divided equally into remimazolam and midazolam groups.

  • 5

    Findings suggest remimazolam may be associated with lower delirium incidence and improved recovery metrics in ECMO patients.

Original Source(s)

Clinical outcomes of a remimazolam-based sedation regimen in patients receiving ECMO: a retrospective comparative study

  • by Dalong Zhang, Ying Liu, Tongrui Zhang, Yuanjie Shang, Huijun Dong, Xingguo Niu

  • June 8, 2026

Related Content

Utilizing CT chest imaging for the diagnosis and monitoring of COVID infections and emergency intensive care unit strategic treatment

When seasonal structure dominates: rethinking causal attribution in environmental epidemiology

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study